Bicara Therapeutics (BCAX) Amortization of Deferred Charges (2024 - 2026)
Bicara Therapeutics' (BCAX) quarterly Amortization of Deferred Charges came in at $273000.0 in Q1 2026, up 97.83% year-on-year from $138000.0 in Q1 2025, and up 9.64% quarter-over-quarter from $249000.0 in Q3 2025.
Bicara Therapeutics (BCAX) Amortization of Deferred Charges (2024 - 2026) Analysis & Trends
Bicara Therapeutics' Amortization of Deferred Charges history runs 3 years deep, the most recent figure standing at $273000.0 for Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.65 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.94 Bn | 114.69 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.85 Bn | 61.09 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - |
| 8 | Argenx Se | 55.74 Bn | 50.56 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - |
| 10 | Bicara Therapeutics | 1.71 Bn | 1.71 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 273,000.00 |
| Mar 31, 2026 | 273,000.00 |
| Sep 30, 2025 | 249,000.00 |
| Sep 30, 2025 | 249,000.00 |
| Jun 30, 2025 | 211,000.00 |
| Jun 30, 2025 | 211,000.00 |
| Mar 31, 2025 | 138,000.00 |
| Mar 31, 2025 | 138,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Sep 30, 2024 | 68,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Jun 30, 2024 | 66,000.00 |
| Mar 31, 2024 | 65,000.00 |
| Mar 31, 2024 | 65,000.00 |